Foretinib (GSK1363089): ATP-Competitive Multikinase Inhibitor for Cancer Research

Executive Summary: Foretinib (GSK1363089), available from APExBIO, is a well-characterized, small-molecule ATP-competitive inhibitor targeting multiple receptor tyrosine kinases including VEGFR and HGF/Met, with IC50 values in the nanomolar range (Schwartz 2022). It effectively blocks tumor cell proliferation, migration, and invasion across various cell lines (APExBIO Product Page). Foretinib's validated in vitro and in vivo efficacy, including significant reduction of metastatic tumor burden in xenograft models, underpins its value as a research tool. Its solubility profile, storage conditions, and experimental integration parameters are well-defined (Dimesna: Mechanistic Profile). This article synthesizes peer-reviewed and manufacturer data to support robust cancer research applications.

Biological Rationale

Receptor tyrosine kinases (RTKs) such as VEGFR, Met (HGFR), and related kinases drive tumor angiogenesis, proliferation, and metastasis. Aberrant signaling via these pathways contributes directly to cancer progression and resistance to standard therapies. Targeted inhibition of these RTKs can disrupt tumor cell survival and spread (Schwartz 2022). Foretinib (GSK1363089) is designed to inhibit multiple RTKs with high potency, making it suitable for dissecting VEGF and HGF/Met signaling mechanisms in oncology research. Its multikinase activity enables the study of both cell-intrinsic and microenvironmental factors influencing tumor biology.

Mechanism of Action of Foretinib (GSK1363089)

Foretinib is an ATP-competitive inhibitor. It binds to the ATP-binding pocket of its target kinases, preventing phosphorylation events critical for downstream signaling. The primary targets are:

• VEGFR2 (KDR): IC50 ~0.9 nmol/L
• Met (HGFR): IC50 ~0.4 nmol/L
• Ron, Flt-1, Flt-4, KIT, Flt-3, PDGFR α/β, Tie-2: IC50 range 0.4–9.6 nmol/L

Foretinib blocks HGF-induced cell motility and promotes G2/M cell cycle arrest, thereby suppressing proliferation. By inhibiting VEGF and HGF/Met pathways, it reduces angiogenesis and impedes metastatic spread (Translational Leverage). Cellular assays confirm its efficacy in murine B16F10 melanoma, PC-3 prostate, A549 lung, and HT29 colon cancer cell lines, with cellular MET inhibition IC50 values of 21–23 nmol/L.

Evidence & Benchmarks

• Foretinib inhibits Met, VEGFR2, and other RTKs with IC50 values between 0.4–9.6 nmol/L in biochemical assays (Schwartz 2022).
• It suppresses tumor cell proliferation and migration in B16F10, PC-3, A549, and HT29 cell lines in vitro (APExBIO Product Page).
• Cellular MET inhibition is achieved with IC50 values of 21–23 nmol/L under serum-free conditions in standard kinase assays (Dimesna: Mechanistic Profile).
• Oral administration at 30 mg/kg in mice significantly reduces metastatic tumor nodules and tumor weight in ovarian cancer xenografts (Schwartz 2022, Table 2.3).
• Foretinib is soluble at ≥31.65 mg/mL in DMSO at 25°C, but insoluble in water and ethanol (APExBIO Product Page).

These quantitative benchmarks support Foretinib's role as a reference compound for studying multikinase inhibition in cancer.

Applications, Limits & Misconceptions

Foretinib is intended for scientific research use only. Its validated applications include:

• Cell viability and proliferation assays in cancer cell lines
• Cell motility and invasion assays (HGF-induced migration)
• In vivo tumor growth and metastasis models (e.g., ovarian cancer xenograft)
• Pathway mapping for VEGF and HGF/Met signaling

For a detailed discussion of assay integration and troubleshooting, see "Solving Assay Challenges with Foretinib", which addresses practical issues in workflow optimization. This article extends those findings by providing in-depth molecular benchmarks and clarifying solubility/storage parameters.

Common Pitfalls or Misconceptions

• Foretinib is not water- or ethanol-soluble; DMSO is required for preparing stock solutions.
• It is not suitable for diagnostic or therapeutic (clinical) use; research use only.
• Activity is context-dependent; efficacy and IC50 values may vary across cell types and assay conditions.
• Stock solutions are sensitive to degradation; storage at -20°C and prompt use are mandatory.
• Single-agent Foretinib does not universally suppress all tumor types; pathway redundancy may confer resistance in some models.

Workflow Integration & Parameters

For optimal results, dissolve Foretinib (A2974) at ≥31.65 mg/mL in DMSO at room temperature (25°C). Vortex or sonicate to ensure complete dissolution. Store aliquots at -20°C, protected from light. Use freshly prepared working solutions to prevent degradation.

Recommended applications:

• Cell-based assays: Dilute to final concentrations (e.g., 10–100 nM) in serum-free or low-serum media. Confirm DMSO content does not exceed 0.1% (v/v) in assay wells.
• In vivo xenografts: Oral dosing at 30 mg/kg daily has demonstrated significant tumor inhibition in murine models (Schwartz 2022).
• Readouts: Use cell viability (MTT, CellTiter-Glo), migration/invasion (Transwell), and immunoblotting for phospho-kinase analysis.

For advanced methodologies and translational applications, see "Translational Leverage: Mechanistic and Strategic Pathway Integration". This article expands upon those concepts with updated experimental parameters and molecular specificity.

For comparison with similar multikinase inhibitors and further workflow guidance, refer to "Foretinib: Multikinase Inhibitor for Precision Quantification", which focuses on quantitative readouts across multiple cell lines. The present article clarifies storage and solubility constraints, which are often overlooked in experimental planning.

Conclusion & Outlook

Foretinib (GSK1363089) offers a robust, validated platform for dissecting VEGFR and HGF/Met signaling in cancer research. Its nanomolar potency, broad kinase selectivity, and well-defined experimental parameters support reproducible, mechanistically insightful studies. As a research-use-only compound from APExBIO, Foretinib is not for clinical application but rather for generating foundational insights into tumor biology and therapeutic resistance. Ongoing research may further illuminate its role in combination strategies and resistance modeling (Schwartz 2022).

For ordering or additional technical details, visit the Foretinib (GSK1363089) product page.